Hans‐Helge Müller

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Massimo Terzolo, Bruno Allolio, Éric Baudin et al. · New England Journal of Medicine · 2012 · 845 citations · Full text

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival

Anja Rinke, Michael Wittenberg, Carmen Schade‐Brittinger et al. · Neuroendocrinology · 2016 · 373 citations

Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches

Hans‐Helge Müller, H. Schäfer · Biometrics · 2001 · 367 citations

Engineering, Optimal Experimental Design, Quasi-experiment +16

Randomized Trial of Surgery Versus Surgery Followed by Adjuvant Hepatic Arterial Infusion With 5-Fluorouracil and Folinic Acid for Liver Metastases of Colorectal Cancer

Matthias Lorenz, Hans‐Helge Müller, H Schramm et al. · Annals of Surgery · 1998 · 358 citations